表紙
市場調查報告書

全球軸心型脊椎關節炎(axSpA)治療市場 2018年∼2022年

Global Axial Spondyloarthritis Treatment Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 728677
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
全球軸心型脊椎關節炎(axSpA)治療市場 2018年∼2022年 Global Axial Spondyloarthritis Treatment Market 2018-2022
出版日期: 2018年10月16日內容資訊: 英文 108 Pages
簡介

關於軸心型脊椎關節炎(axSpA)治療

軸心型脊椎關節炎(axSpA)治療市場,主要是以影響脊椎及骶髂關節的發炎性風濕疾病治療所使用的藥品為對象。

Technavio的分析師預測,在2018年到2022年間,全球軸心型脊椎關節炎(axSpA)治療市場將以7.37%的年複合成長率成長。

本報告提供全球軸心型脊椎關節炎(axSpA)治療市場調查,市場概要,各類別、各地區的市場規模變化與預測,市場趨勢,市場成長要素及課題分析,開發平台趨勢,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模及預測

第6章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係
  • 市場情形

第7章 開發平台概要

第8章 市場區隔:各類別

  • 市場區隔:各類別
  • 市場比較:各類別
  • 強直性軸心型脊椎關節炎
  • 非X光線性軸心型脊椎關節炎
  • 市場機會:各類別

第9章 客戶形勢

第10章 地區形勢

  • 市場區隔:各地區
  • 市場比較:各地區
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

第14章 業者情勢

  • 概要
  • 創造性破壞狀況

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Pfizer
  • UCB

第16章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR23587

About Axial Spondyloarthritis Treatment

Axial spondyloarthritis treatment market covers the drugs used for the treatment of inflammatory rheumatic disease, which predominantly affects the spine and sacroiliac joints.

Technavio's analysts forecast the Global Axial Spondyloarthritis Treatment Market to grow at a CAGR of 7.37% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the axial spondyloarthritis treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of axial spondyloarthritis across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Axial Spondyloarthritis Treatment Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Pfizer
  • UCB

Market driver

  • Increase in the number of approved biosimilars
  • For a full, detailed list, view our report

Market challenge

  • High cost of biologics
  • For a full, detailed list, view our report

Market trend

  • Increase in the number of small molecules in the drug development pipeline
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY CATEGORY

  • Segmentation by category
  • Comparison by category
  • Global ankylosing spondylitis treatment market - Market size and forecast 2017-2022
  • Global non-radiographic axial spondyloarthritis treatment market - Market size and forecast 2017-2022
  • Market opportunity by category

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Pfizer
  • UCB

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global axial spondyloarthritis treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global axial spondyloarthritis treatment market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 09: Global axial spondyloarthritis treatment market - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase 2018
  • Exhibit 19: Key clinical trial candidates of axial spondyloarthritis 2017-2018
  • Exhibit 20: Global axial spondyloarthritis treatment market by category- Market share 2017-2022 (%)
  • Exhibit 21: Comparison by category
  • Exhibit 22: Global ankylosing spondylitis treatment market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 23: Global ankylosing spondylitis treatment market - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Global non-radiographic axial spondyloarthritis treatment market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Global non-radiographic axial spondyloarthritis treatment market - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by category
  • Exhibit 27: Customer landscape
  • Exhibit 28: Global axial spondyloarthritis treatment market by geography - Market share 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Top 3 countries in the Americas
  • Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: AbbVie: Overview
  • Exhibit 46: AbbVie - Business segments
  • Exhibit 47: AbbVie - Organizational developments
  • Exhibit 48: AbbVie - Geographic focus
  • Exhibit 49: AbbVie - Key offerings
  • Exhibit 50: AbbVie - Key customers
  • Exhibit 51: Amgen: Overview
  • Exhibit 52: Amgen - Business segments
  • Exhibit 53: Amgen - Organizational developments
  • Exhibit 54: Amgen - Geographic focus
  • Exhibit 55: Amgen - Key offerings
  • Exhibit 56: Amgen - Key customers
  • Exhibit 57: Johnson & Johnson: Overview
  • Exhibit 58: Johnson & Johnson- Business segments
  • Exhibit 59: Johnson & Johnson- Organizational developments
  • Exhibit 60: Johnson & Johnson- Geographic focus
  • Exhibit 61: Johnson & Johnson- Segment focus
  • Exhibit 62: Johnson & Johnson- Key offerings
  • Exhibit 63: Johnson & Johnson- Key customers
  • Exhibit 64: Pfizer: Overview
  • Exhibit 65: Pfizer - Business segments
  • Exhibit 66: Pfizer - Organizational developments
  • Exhibit 67: Pfizer - Geographic focus
  • Exhibit 68: Pfizer- Segment focus
  • Exhibit 69: Pfizer - Key offerings
  • Exhibit 70: Pfizer - Key customers
  • Exhibit 71: UCB: Overview
  • Exhibit 72: UCB - Business segments
  • Exhibit 73: UCB - Organizational developments
  • Exhibit 74: UCB - Geographic focus
  • Exhibit 75: UCB - Key offerings
  • Exhibit 76: UCB - Key customers